|
Activity Number:
|
148
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Monday, July 30, 2007 : 10:30 AM to 12:20 PM
|
|
Sponsor:
|
Section on Health Policy Statistics
|
| Abstract - #309826 |
|
Title:
|
Characterizing Drug Diffusion with Patient-Level Data
|
|
Author(s):
|
Camelia Sima*+ and Katherine Panageas and Glenn Heller and Deborah Schrag
|
|
Companies:
|
MSKCC and MSKCC and MSKCC and MSKCC
|
|
Address:
|
307 E 63rd Street 3rd floor, New York, NY, 10021,
|
|
Keywords:
|
drug diffusion ; competing risks ; bivariate cumulative incidence function
|
|
Abstract:
|
To inform assessments of the quality of cancer care, we investigate different trends of chemotherapy drugs subsequent to FDA approval, as functions of tumor type and patient characteristics. The event of interest is the time to first drug utilization by an eligible patient, and the analysis is complicated by dependent censoring for death. Diffusion is estimated through a bivariate cumulative incidence function, accounting for death as a competing risk. The two components are time from cancer diagnosis to first utilization of the drug, and calendar time. The relation between the components is of interest in order to understand how drug adoption is related to the time elapsed since FDA approval. We apply the method to SEER-Medicare data and test the hypothesis that worse prognosis and younger age at diagnosis are correlated with accelerated drug diffusion.
|
